BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 29358004)

  • 1. Hematologists' Preferences for First-line Therapy Characteristics for Multiple Myeloma in Japan: Attribute Rating and Discrete Choice Experiment.
    Bolt T; Mahlich J; Nakamura Y; Nakayama M
    Clin Ther; 2018 Feb; 40(2):296-308.e2. PubMed ID: 29358004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alignment of preferences in the treatment of multiple myeloma - a discrete choice experiment of patient, carer, physician, and nurse preferences.
    Fifer SJ; Ho KA; Lybrand S; Axford LJ; Roach S
    BMC Cancer; 2020 Jun; 20(1):546. PubMed ID: 32527324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of physicians' perspectives versus patients' preferences: direct assessment and discrete choice experiments in the therapy of multiple myeloma.
    Mühlbacher AC; Nübling M
    Eur J Health Econ; 2011 Jun; 12(3):193-203. PubMed ID: 20107856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment preferences of patients with relapsed or refractory multiple myeloma in the United States, United Kingdom, Italy, Germany, France, and Spain: results from a discrete choice experiment.
    Thomas C; Ailawadhi S; Popat R; Kleinman D; Ross MM; Gorsh B; Mulnick S; O'Neill A; Paka P; Hanna M; Krucien N; Molinari A; Gelhorn HL; Perera S
    Front Med (Lausanne); 2023; 10():1271657. PubMed ID: 38076274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding preferences for HIV care and treatment in Zambia: Evidence from a discrete choice experiment among patients who have been lost to follow-up.
    Zanolini A; Sikombe K; Sikazwe I; Eshun-Wilson I; Somwe P; Bolton Moore C; Topp SM; Czaicki N; Beres LK; Mwamba CP; Padian N; Holmes CB; Geng EH
    PLoS Med; 2018 Aug; 15(8):e1002636. PubMed ID: 30102693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival or Mortality: Does Risk Attribute Framing Influence Decision-Making Behavior in a Discrete Choice Experiment?
    Veldwijk J; Essers BA; Lambooij MS; Dirksen CD; Smit HA; de Wit GA
    Value Health; 2016; 19(2):202-9. PubMed ID: 27021754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing Analytic Hierarchy Process and Discrete-Choice Experiment to Elicit Patient Preferences for Treatment Characteristics in Age-Related Macular Degeneration.
    Danner M; Vennedey V; Hiligsmann M; Fauser S; Gross C; Stock S
    Value Health; 2017 Sep; 20(8):1166-1173. PubMed ID: 28964450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physician preferences for chemotherapy in the treatment of non-small cell lung cancer in China: evidence from multicentre discrete choice experiments.
    Sun H; Wang H; Shi L; Wang M; Li J; Shi J; Ni M; Hu X; Chen Y
    BMJ Open; 2020 Feb; 10(2):e032336. PubMed ID: 32051302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients' and hematologists' concerns regarding tyrosine kinase-inhibitor therapy in chronic myeloid leukemia.
    Jiang Q; Yu L; Gale RP
    J Cancer Res Clin Oncol; 2018 Apr; 144(4):735-741. PubMed ID: 29380058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does attribute framing in discrete choice experiments influence willingness to pay? Results from a discrete choice experiment in screening for colorectal cancer.
    Howard K; Salkeld G
    Value Health; 2009; 12(2):354-63. PubMed ID: 18657102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physicians' preferences for bone metastases drug therapy in the United States.
    Arellano J; Hauber AB; Mohamed AF; Gonzalez JM; Collins H; Hechmati G; Gatta F; Qian Y
    Value Health; 2015 Jan; 18(1):78-83. PubMed ID: 25595237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing the Relative Importance of Attributes of Metastatic Renal Cell Carcinoma Treatments to Patients and Physicians in the United States: A Discrete-Choice Experiment.
    González JM; Doan J; Gebben DJ; Boeri M; Fishman M
    Pharmacoeconomics; 2018 Aug; 36(8):973-986. PubMed ID: 29869777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient and Physician Preferences for Therapy Characteristics for Psoriasis: A Discrete Choice Experiment in Japan.
    Bolt T; Kobayashi H; Mahlich J
    Pharmacoecon Open; 2019 Jun; 3(2):255-264. PubMed ID: 30377992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discrete-choice experiments versus rating scale exercises to evaluate the importance of attributes.
    Wijnen BF; van der Putten IM; Groothuis S; de Kinderen RJ; Noben CY; Paulus AT; Ramaekers BL; Vogel GC; Hiligsmann M
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):721-8. PubMed ID: 25835045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients' Preferences for the Treatment of Metastatic Castrate-resistant Prostate Cancer: A Discrete Choice Experiment.
    Eliasson L; de Freitas HM; Dearden L; Calimlim B; Lloyd AJ
    Clin Ther; 2017 Apr; 39(4):723-737. PubMed ID: 28366592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating patients' preferences for multiple myeloma therapy, a Discrete-Choice-Experiment.
    Mühlbacher AC; Lincke HJ; Nübling M
    Psychosoc Med; 2008 Dec; 5():Doc10. PubMed ID: 19742282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What Do Patients Want from Otolaryngologists? A Discrete Choice Experiment.
    Naunheim MR; Rathi VK; Naunheim ML; Alkire BC; Lam AC; Song PC; Shrime MG
    Otolaryngol Head Neck Surg; 2017 Oct; 157(4):618-624. PubMed ID: 28675119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient Preferences for Attributes of Chemotherapy for Lung Cancer: Discrete Choice Experiment Study in Japan.
    Sugitani Y; Ito K; Ono S
    Front Pharmacol; 2021; 12():697711. PubMed ID: 34354590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What Are the Attributes Prioritized in the Choice of Therapy in Chronic Lymphocytic Leukemia? A Patient-physician Cross-matching Analysis of a Discrete Choice Experiment.
    Laurenti L; Gaidano G; Mauro FR; Molica S; Pasqualetti P; Scarfò L; Ghia P
    Hemasphere; 2022 Sep; 6(9):e771. PubMed ID: 36081648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding Clinician Preferences for Treatment Attributes in Oncology: A Discrete Choice Experiment of Oncologists' and Urologists' Preferences for First-Line Treatment of Locally Advanced/Unresectable Metastatic Urothelial Carcinoma in Five European Countries.
    Panattoni L; Kearney M; Land N; Flottemesch T; Sullivan P; Kirker M; Bharmal M; Hauber B
    Pharmacoeconomics; 2024 Mar; ():. PubMed ID: 38472738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.